HeartBeam, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $5.0 million, a slight increase from the $4.97 million loss recorded in the same period of the previous year. For the six months ending June 30, 2026, the company’s net loss was $9.74 million, compared to $10.46 million for the first half of 2025. The company’s total operating expenses for the second quarter were $5.09 million, a marginal increase of 1% from $5.04 million in the prior year. The increase in expenses was primarily driven by a 62% rise in selling, general, and administrative expenses, attributed to non-cash stock-based compensation and severance costs related to the former CEO.
In terms of liquidity, HeartBeam reported cash and cash equivalents of approximately $8.72 million as of June 30, 2026, a significant increase from $4.38 million at the end of 2025. This increase was bolstered by gross proceeds of approximately $11.5 million from a public offering completed in April 2026. However, the company noted that its existing cash reserves may not be sufficient to fund operations for the next twelve months, raising concerns about its ability to continue as a going concern.
Operationally, HeartBeam has not generated any revenue from its HeartBeam System during the reported periods. The company is focused on advancing its product offerings, including a novel 12-lead ECG patch, which is currently undergoing a pilot study in Serbia. The company aims to expand its market presence through strategic partnerships, including agreements with ClearCardio and Atelier Health, to facilitate the adoption of its technology in preventive cardiology practices across multiple U.S. regions.
The company has also undergone significant organizational changes, including the transition of Rob Eno from CEO to a consulting role, with Branislav Vajdic stepping in as the principal executive officer. As of June 30, 2026, HeartBeam employed 16 individuals. The company is actively pursuing additional capital to support its operations and product development, while also navigating the challenges of maintaining compliance with Nasdaq listing requirements, following a deficiency notice regarding its stock price.
Looking ahead, HeartBeam is focused on leveraging its proprietary 3D ECG technology to capture a share of the growing cardiac monitoring market, estimated at $40 billion. The company plans to continue its limited commercial launch of the HeartBeam System while exploring opportunities for licensing its technology to third-party partners. The management remains optimistic about achieving critical clinical and regulatory milestones that could enhance its market position and facilitate future funding opportunities.
About HeartBeam, Inc.
HeartBeam, Inc. develops portable, FDA-cleared cardiac monitoring devices utilizing proprietary technology to capture high-fidelity ECG signals from three directions. Its products enable remote detection and diagnosis of cardiac conditions, including arrhythmias and heart attacks, through user-friendly, cable-free hardware and cloud-based software. Targeting healthcare providers and patients, the company aims to improve early diagnosis, reduce healthcare costs, and expand advanced cardiac diagnostics outside clinical settings.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov